文献速递肝病

标准化非酒精性脂肪性肝病临床试验中肝活检的组织学评估

Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials.
PubMed 文献 · Aliment Pharmacol Ther · 2019-10-03

该研究通过改良RAND/UCLA appropriateness方法,由14名肝脏病理学家和3名肝病学家组成的专家小组对130个条目进行评分,旨在建立非酒精性脂肪性肝病(NAFLD)临床试验中肝活检组织学评估的标准化框架。专家认为现有疾病活动度和纤维化指标可能未完全捕捉NASH重要特征,需改进气球样变评估方法,并需共识定义桥接纤维化及亚分期。

要点

  • 现有指标可能未完全反映NASH特征,需改进气球样变评估。
  • 需共识定义桥接纤维化亚分期并评估纤维化消退特征。
  • 所提修改的操作特性需前瞻性评估信度和反应度。

核心结论

  • 应前瞻性评估所提修改的操作特性以确定信度和反应度。

研究设计与样本

  • 由14名肝脏病理学家和3名肝病学家组成专家小组,采用改良RAND/UCLA appropriateness方法对130个条目进行评分。

主要发现

  • 现有疾病活动度和纤维化指标可能未完全捕捉NASH重要特征。
  • 评估气球样变的方法需要改进。
  • 专家对门管区炎症、脂肪变程度和Mallory-Denk小体是否为重要疾病活动度指标不确定。
  • 现有分期系统未涵盖NASH纤维化全谱,需共识定义桥接纤维化及亚分期。
  • 应开发评估纤维化消退特征的方法。

关键数值与推荐

  • 条目分类:不适当为 median 1-3.5 且无分歧;不确定为 median 3.5-6.5 或任何有分歧的中位数;适当为 median 6.5-9 且无分歧。
  • 分歧定义为最低(1-3)和最高(7-9)类别中至少5个评分。

临床怎么用

  • 临床试验中肝活检组织学评估应参考此共识框架,关注气球样变评估改进和桥接纤维化亚分期。

局限性

  • 所提修改的信度和反应度尚未前瞻性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is substantial variation in how histologic definitions and scoring systems of non-alcoholic fatty liver disease (NAFLD) are operationalised. AIM: To develop a consensus-based framework for standardising histologic assessment of liver biopsies in clinical trials of NAFLD. METHODS: An expert panel of 14 liver pathologists and three hepatologists was assembled. Using modified RAND/University of California Los Angeles appropriateness methodology, 130 items derived from literature review and expert opinion were rated by each panel member on a 1-9 scale. Disagreement was defined as ≥5 ratings in the lowest (1-3) and highest (7-9) categories. Items were classified as inappropriate (median 1-3.5 without disagreement), uncertain (median 3.5-6.5 or any median with disagreement) or appropriate (median 6.5-9 without disagreement). Survey results were discussed as a group before voting. RESULTS: Current measures of disease activity and fibrosis may not fully capture important features of non-alcoholic steatohepatitis (NASH). Alternative methods to evaluate ballooning degeneration are needed. Panellists were uncertain whether portal inflammation, degree of steatosis and Mallory-Denk bodies are important measures of disease activity. Furthermore, it was felt that current staging systems do not capture the full spectrum of fibrosis in NASH. A consensus definition and sub-stages for bridging fibrosis are needed. The severity of perisinusoidal fibrosis should be captured at all stages. Lastly, a method to evaluate features of fibrosis regression should be developed. CONCLUSION: The operating properties of the modifications proposed should be evaluated prospectively to determine reliability and responsiveness.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Pai RK, Kleiner DE, Hart J, et al. Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. Aliment Pharmacol Ther. 2019. PMID: 31583739. doi:10.1111/apt.15503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。